Results 11 to 20 of about 43,675 (258)
EZH2 in Myeloid Malignancies [PDF]
Cells, 2020 Our understanding of the significance of epigenetic dysregulation in the pathogenesis of myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for gene silencing through trimethylation of H3K27. EZH2 dysregulation
Jenny Rinke +4 more
openaire +3 more sources
Journal of the Advanced Practitioner in Oncology, 2022 Epigenetic regulation is a novel approach to cancer treatment. Inhibition of enhancer of zeste homolog 2 (EZH2) is a method to provide targeted epigenetic regulation. Tazemetostat is a first-in-class targeted epigenetic regulator that specifically inhibits EZH2.
Straining, Rachael, Eighmy, William
openaire +2 more sources
Targeting EZH2 in cancer [PDF]
Nature Medicine, 2016 Recent genomic studies have resulted in an emerging understanding of the role of chromatin regulators in the development of cancer. EZH2, a histone methyl transferase subunit of a Polycomb repressor complex, is recurrently mutated in several forms of cancer and is highly expressed in numerous others.
Kimberly H, Kim, Charles W M, Roberts
openaire +2 more sources
Targeting EZH2 as cancer therapy [PDF]
The Journal of Biochemistry, 2021 Abstract Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2) that mediate repression of target genes by trimethylation of Lys27 in histone 3 (H3K27me3). Given the reported roles of EZH2 in cancer, it is perhaps not surprising that targeting EZH2 in cancer therapy has become a hot research ...
Shunsuke Hanaki, Midori Shimada
openaire +2 more sources
Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer [PDF]
Nature Chemical Biology, 2013 Enhancer of zeste homolog 2 (EZH2) is the histone lysine N-methyltransferase component of the Polycomb repressive complex 2 (PRC2), which, in conjunction with embryonic ectoderm development (EED) and suppressor of zeste 12 homolog, regulates cell lineage determination and homeostasis.
Kim, Woojin +6 more
openaire +4 more sources
EZH2: a pleiotropic protein [PDF]
Blood, 2016 In this issue of Blood , [Yan et al][1] report their findings in natural killer/T-cell lymphoma (NKTL) and present experimental evidence that EZH2 can act as a transcriptional activator, independent of its methyltransferase activity, when phosphorylated by JAK3.
openaire +2 more sources
Journal of Veterinary Research, 2022 Enhancer of zeste homologue 2 (EZH2) is the human homologue of Drosophila zeste gene enhancer. The aim of this study was to determine the expression of EZH2 in canine mammary carcinomas (CMCs) and its relationship with clinicopathological features.
Ren Xiaoli +4 more
doaj +1 more source
EZH2: Not EZHY (Easy) to Deal [PDF]
Molecular Cancer Research, 2014 Abstract Seminal discoveries have established that epigenetic modifications are important for driving tumor progression. Polycomb group (PcG) proteins are highly conserved epigenetic effectors that maintain, by posttranslational modification of histones, the silenced state of genes involved in critical biologic processes, including ...
Gauri, Deb +2 more
openaire +2 more sources
EZH2: An Accomplice of Gastric Cancer
Cancers, 2023 Gastric cancer is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Understanding the factors influencing the therapeutic effects in gastric cancer patients and the molecular mechanism behind gastric cancer is still facing challenges.
Yu, Wuhan +8 more
openaire +2 more sources
Radiology and Oncology, 2019 Endometrial cancer (EC) is one of the most common gynaecological tumours in the worldwide. Long non-coding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) promotes cell proliferation, migration and invasion in EC cells. However, the molecular
Wang Wei +6 more
doaj +1 more source